Pseudoneutralizing test for preclinical studies of vaccines against SARS-CoV-2

QR Code

Pseudoneutralizing test for preclinical studies of vaccines against SARS-CoV-2

The purpose of this study was to evaluate efficiency of a competitive enzyme immunoassay which specifically detects antibodies that recognize the receptor-binding domain at the S1 subunit of SARS-CoV-2 coronavirus spike protein and block the formation of initiator infection complex between RBD and a...

Full description

Saved in:

Bibliographic Details
Main Authors:	B. S. Cherepovich, A. M. Kudryashova, N. P. Kartashova, A. V. Gracheva, V. A. Manuilov, I. A. Leneva, O. V. Borisova, O. A. Svitich
Format:	Article
Language:	Russian
Published:	St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists 2024-04-01
Series:	Медицинская иммунология
Subjects:	covid-19 sars-cov-2 solid-phase elisa virus-neutralizing antibodies pseudo-neutralizing test blood serum animals
Online Access:	https://www.mimmun.ru/mimmun/article/view/2905
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Total antibodies and neutralizing ability of convalescent sera against three different strains of SARS-CoV-2
by: Natalia V. Palyanova, et al.
Published: (2025-03-01)

Determination of t cell immune response to SARS-CoV-2 coronavirus based on induced γ-interferon production by specific T cells upon their stimulation by viral antigen
by: B. S. Cherepovich, et al.
Published: (2025-01-01)

Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1
by: Shuo Liu, et al.
Published: (2023-12-01)

«DELTA-VAC» SUBUNIT VACCINE INDUCES STRONG HUMORAL IMMUNE RESPONSE AGAINST SARS-COV-2
by: Valentina Sergeevna Nesmeyanova, et al.
Published: (2019-08-01)

Seroprevalence and influencing factors of low-level neutralizing antibodies against SARS-CoV-2 in community residents
by: YUAN Shiying, et al.
Published: (2025-05-01)

Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination
by: Rahul K. Suryawanshi, et al.
Published: (2023-12-01)

Neutralising and Non-neutralising Antibodies to SARS-CoV-2: Role during Infection and in the Evolution of Antigenic structure
by: S. K. Pylaeva, et al.
Published: (2025-01-01)

DEVELOPMENT AND VALIDATION OF A METHOD FOR DETERMINING NEUTRALIZING ANTIBODIES TO PEMBROLIZUMAB IN HUMAN SERUM BASED ON INHIBITION OF BINDING OF PEMBROLIZUMAB TO ITS PD-1 TARGET BY ELISA
by: A. M. Kudryashova, et al.
Published: (2019-08-01)

Neutralizing Antibody Spectrum in COVID-19 Patients who Became Ill During the Circulation of Different SARS-CoV-2 Variants
by: S. K. Pylaeva, et al.
Published: (2024-11-01)

An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV
by: Hailong Guo, et al.
Published: (2023-12-01)

SARS-CoV-2 spike S2-specific neutralizing antibodies
by: Chia-Jung Li, et al.
Published: (2023-12-01)

Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector
by: Ziteng Liang, et al.
Published: (2023-12-01)

Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1
by: Yanping Hu, et al.
Published: (2023-12-01)

Cross-neutralization ability of anti-MERS-CoV monoclonal antibodies against a variety of merbecoviruses
by: Lin Pan, et al.
Published: (2025-07-01)

Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels
by: Ren-qiang LIU, et al.
Published: (2017-10-01)

THE NEUTRALITY OF THE REPUBLIC OF BELARUS AS LEGAL PROVISION
by: O. I. Chupris, et al.
Published: (2018-04-01)

SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters1
by: Biao Zhou, et al.
Published: (2023-12-01)

Monoclonal Antibodies Capable of Inhibiting the Interaction of the Receptor Binding Domain of SARS-CoV-2 Virus with the Angiotensin-Converting Receptor 2 of Human Cells
by: T. A. Ivashchenko, et al.
Published: (2024-10-01)

Serological Surveillance of Betacoronaviruses in Bat Guano Collectors: Pre-COVID-19 Pandemic and Post-SARS-CoV-2 Emergence
by: Sasiprapa Ninwattana, et al.
Published: (2025-06-01)

Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum Protection
by: Rui Qiao, et al.
Published: (2025-06-01)

Genetic and Immunological Profiling of Recent SARS-CoV-2 Omicron Subvariants: Insights into Immune Evasion and Infectivity in Monoinfections and Coinfections
by: Nadine Alvarez, et al.
Published: (2025-06-01)

Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3
by: Julia N. Faraone, et al.
Published: (2023-12-01)

The Actuality of the Permanent Neutrality of a State in Contemporary International Law
by: R. Czachor
Published: (2021-10-01)

Characteristics of erythropoietin antibodies in patients treated with recombinant human erythropoietin
by: A. M. Kudryashova, et al.
Published: (2020-01-01)

Discovery of Synergistic Broadly Neutralizing Antibodies Targeting Non-Dominant Epitopes on SARS-CoV-2 RBD and NTD
by: Hualong Feng, et al.
Published: (2025-05-01)

Seroprevalence study results to SARS-CoV-2 in healthcare workers: age and professional aspects
by: E. V. Agafonova, et al.
Published: (2021-05-01)

Selection of a SARS-CoV-2 antibody quantification method and development of an antibody reference standard for ELISA to test immunoglobulin preparations
by: T. I. Smolyanova, et al.
Published: (2022-12-01)

Presence of neutralizing SARS‐CoV‐2 antibodies in asymptomatic population of N'Djamena, Chad
by: Andrillene Laure Deutou Wondeu, et al.
Published: (2024-01-01)

Detection of antibodies to erythropoietin-based drugs: is it possible to create the universal test system?
by: A. M. Kudryashova, et al.
Published: (2021-06-01)

The Problems of Using a Gender-Neutral Language in Germany
by: Ju. G. Timralieva, et al.
Published: (2025-06-01)

MACROECONOMIC BALANCE AND NEUTRAL MONETARY POLICY
by: V. K. Krylov
Published: (2020-09-01)

Immunogenicity of experimental DNA vaccines encoding hemagglutinin and hemagglutinin stalk of influenza A (H5N8) virus
by: V. R. Litvinova, et al.
Published: (2025-02-01)

Neutralizing antibody response to different COVID-19 vaccines in Brazil: the impact of previous infection and booster doses
by: Beatriz L. L. Caetano, et al.
Published: (2025-08-01)

Development and Validation of a Standardized Pseudotyped Virus-Based Neutralization Assay for Assessment of Anti-Nipah Virus Neutralizing Activity in Candidate Nipah Vaccines
by: Muntasir Alam, et al.
Published: (2025-07-01)

Mission Possible - The Mission on Climate Neutral and Smart Cities A new approach to sustainable urban transformation and urban transition to climate neutrality
by: Chrysses Nicolaides
Published: (2021-12-01)

Development and Validation of ELISA for In Vitro Diagnosis of SARS-CoV-2 Infection
by: Larissa de Carvalho Medrado Vasconcelos, et al.
Published: (2025-07-01)

Oscillations of First Order Neutral Differential Equations with Positive and Negative Coefficients
by: Baghdad Science Journal
Published: (2014-12-01)

Methods and technologies of disposal of poly-chloride biphenyls in transformer oils
by: V. M. Bel’Kov
Published: (2016-02-01)

Vaccination against SARS-COV‑2 in oncology
by: A. A. Polyakov, et al.
Published: (2021-06-01)

Immunological Approaches and Different Strategies for Vaccine Development Against SARS-COV-2
by: Muhammed Babakir-Mina
Published: (2020-12-01)